Navigation Links
For Multiple Sclerosis Treatment, Prescriber Base for Genzyme's Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch
Date:5/30/2013

EXTON, Pa., May 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that over half of surveyed neurologists have prescribed Aubagio, the second oral disease-modifying agent (DMA) marketed for multiple sclerosis (MS), to at least one of their MS patients at six months post-launch. While this represents a significant increase in prescriber base from one and three months post-launch, it does trail that observed with Gilenya (according to LaunchTrends: Gilenya Wave 3) at the same stage of product launch. This difference in prescriber base between the two oral DMAs is reflected in a smaller Aubagio patient share among DMA-treated relapsing-remitting MS (RR-MS) patients compared with the six-month share reported for Gilenya. Nevertheless, initial uptake of Aubagio continues to be driven by the product's convenient once-daily, oral formulation, with the majority of patients initiated on Aubagio still coming from switches.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

With Biogen Idec's Tecfidera being approved days before current survey fielding, substantial press coverage was given to the comparative wholesale prices across the DMAs, with Aubagio being the least expensive. Data from the LaunchTrends: Aubagio Wave 3 report suggest that this information has not had the expected impact on neurologists' perceptions of Aubagio's cost as significantly more of the 73 surveyed neurologists now perceive Aubagio as being more expensive than the other DMAs compared with previous waves. Furthermore, while current prescribers continue to express high overall satisfaction with Aubagio, especially for its efficacy, they rate their satisfaction with the product's cost significantly lower than at three months post-launch. Qualitative feedback suggests that difficulties with managed care coverage of Aubagio may be having a trickle-down effect on neurologists' perception of Aubagio's price.

"Given that neurologists report currently treating 9 percent of their DMA-treated RR-MS patients with the oral DMAs available at the time of survey fielding (Aubagio and Gilenya), it is interesting to note that surveyed neurologists expect the oral DMA group to capture 23 percent patient share over the next six months," said BioTrends Research Group Analyst Emma Williams , Ph.D. "Although this growth is anticipated to be driven predominantly by Tecfidera uptake, Aubagio patient share is also projected to significantly increase, while Gilenya patient share is expected to remain stable."

Overall, these results highlight neurologists' growing receptivity to oral DMAs and indicate a general shift in the MS treatment algorithm, away from the platform DMAs (Biogen Idec's Avonex, Bayer HealthCare's Betaseron, Teva's Copaxone and Pfizer/EMD Serono's Rebif) and Biogen Idec's Tysabri.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
2. Roskamp Institute Reports Beneficial Effects of Nutritional Supplementation with Anatabine in an Animal Model of Multiple Sclerosis
3. Aushon to Launch New Multiplex Immunoassay Platform
4. Multiple Sclerosis Association of Americas MRI Institute Marks 10 Years of Helping Individuals with Multiple Sclerosis Obtain MRIs
5. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
6. Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally
7. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
8. Life Technologies Develops Simplified SAME-DAY STEC Solution for Detecting Multiple Strains of E. coli in Ground Beef
9. Therapy Trends: Multiple Sclerosis
10. New International Survey Reveals Multiple Barriers to an Accurate and Timely Alzheimers Disease Diagnosis
11. Eutropics Pharmaceuticals signs $1.5M NCI/SBIR contract to develop companion diagnostic for guiding Multiple Myeloma treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):